CD25
1 T regulatory cells (Tregs), which are also positive for Foxp3, the master regulator of Treg development. 1 Tregs are the most prominent regulatory cell type with established functions. Natural Tregs develop in the thymus, and inducible or adaptive Tregs develop in the periphery. The use of Tregs is potentially an attractive therapeutic option in the clinical management of autoimmune diseases or rejection of organ transplantation. However, a lack of stable and specific markers 2 and a lack of antigen specificity has prevented the development of this cell type into a safe and effective cellular therapeutic. Therefore, the identification of novel Tregs that have manageable markers and antigen specificity has important theoretical and practical implications. The number of newly identified Tregs has been increasing. 3 Bandala-Sanchez et al. 4 reported in the May nineteenth issue of Nature Immunology the identification of a novel pancreatic islet autoantigen-specific CD4
1 Treg that expressed high levels of cell surface marker CD52. Soluble CD52 was also used by the cell as an effector molecule for suppression. 4 Therefore, the CD52 molecule is both a surface marker and an effector molecule of this novel regulatory T-cell subset.
This group had previously reported the generation of human CD4
1 regulatory T-cell clones against the pancreatic islet autoantigen glutamic acid decarboxylase (GAD65). These regulatory Tcell clones did not share markers (CD25 and Foxp3) or inhibitory mechanisms with typical Tregs. 5 In the current study, they demonstrated that the suppressive clones differed from non-suppressive clones through increased expression of CD52. Bandala-Sanchez et al. first performed a solid-phase antibody array. They then confirmed analysis of individual clones by flow cytometry. To confirm that high CD52 identified suppressive antigen-specific T cells in the peripheral blood mononuclear cells (PBMC) of healthy donors, carboxyfluorescein diacetate succinimidyl esterlabeled PBMC were stimulated with GAD65 for 7 days. Single-cell clones were generated from T cells separated into four groups based on the expression levels of CD52 (top 5, 10, 20 or bottom 80%) and tested for suppressive functions. Out of a total of 327 clones generated, only 29 were suppressive. Twentyfour clones (83%) were in the top 10% of CD52 high expressing CD4 1 T cells. These T-cell clones were defined as regulatory CD52 hi CD4 
CD4
1 Tregs. Thus, these results collectively suggested the identification of a novel T-cell population with regulatory activity.
The physiological significance of these novel regulatory T cells was supported by data from both human and mouse studies. Human studies demonstrated that the number of CD52 hi CD4
1 T cells specific for GAD65, but not for tetanus toxoid, in PBMC from preclinical and type 1 diabetic patients, was lower than that in PBMC from healthy donors or type 2 diabetic patients. The CD52 hi CD4 1 T cells from healthy donors, but not from preclinical and diabetic patients, were suppressive after reactivation by either tetanus toxoid or GAD65. Additionally, CD52
hi CD4 1 T cells from diabetic patients were suppressive only in response to tetanus toxoid, suggesting an antigen-specific reduction in the activity of this regulatory T cell in preclinical and clinical autoimmune disease. This finding was further confirmed by studies using a mouse model of type 1 diabetes. There was an enhanced onset of diabetes in non-obese diabetic (NOD)-severe combined immunodeficiency mice after an adoptive transfer of splenic cells depleted the CD52 hi CD4
1 T cells from 8-week-old NOD mice. This result was also observed with irradiated young NOD mice that received an adoptive transfer of splenic cells that lacked CD52 1 T cells with disease severity remains to be addressed.
The transwell experiments with a 0.2-mm filter that separates regulatory cells from responder cells but allows soluble molecules to move freely from one side of the filter to the other suggested that the suppressive action of this regulatory cell is independent of cell-cell contact. Instead, it is likely mediated by soluble factors. After ruling out all of the known soluble factors required for the suppressive effect of CD25 1 CD4 1 Tregs, including IL-10 and TGF-b, CD52 was examined as a potential effector molecule because CD52 is a glycosylphosphatidylinositol-anchored cell surface molecule. CD52 can be released into cell culture supernatants after cleavage by phospholipases. This action was confirmed by the presence of cell-free CD52 in the culture supernatants, which were free from exosomes or membrane particles, and was consistent with earlier reports that demonstrated the existence of soluble CD52 in the plasma. 6 The release of soluble CD52 was inhibited by a phospholipase C inhibitor. Interestingly, this inhibitor also reversed the suppressive effect of CD52 hi CD4
1 T cells without affecting the viability of CD52 hi or CD52 lo CD4 1 T cells. The monoclonal antibody, CF1D12, which targets the terminal oligosaccharide moiety of CD52, blocked the suppressive activity of CD52 hi CD4
1 Tcellsbyneutralizingsoluble CD52 and enhancing the proliferative response of PBMC to tetanus toxoid and GAD65.
These results demonstrate a potential therapeutic option for the manipulation of regulatory T cells for the purpose of activating effector immune cells against cancer cells or infection. Interestingly, recombinant CD52 fused with Ig Fc inhibited T-cell responses to T-cell receptor (TCR) stimulation but not to phorbol ester PMA plus ionomycin, suggesting that CD52 targets proximal TCR signaling. This finding was further supported by data demonstrating that CD52 inhibits phosphorylation of Lck and Zap70, two critical kinases proximal to the TCR signaling pathways that are required for activation of T cells in response to antigenic stimulation.
The treatment of recombinant CD52 with endoglycosidase PNGase F, which cleaves the oligosaccharide adjacent to its N-linkage, abolished the suppressive activity of CD52 hi CD4 1 T cells, and a synthetic extracellular CD52 peptide with no carbohydrate modification had no effect on T cells. Furthermore, digestion of CD52-Fc with neuraminidase to remove the terminal sialic acids also abrogated the suppressive activity of CD52-Fc. Together, these data suggest that the terminal carbohydrate modification of the extracellular core of CD52 is required for T-cell suppression. The relevance of this mechanism in the manipulation of these Tregs during infection by pathogenic microorganisms that are equipped with such enzymes remains to be addressed.
Because sialoside structures, like CD52, are known to be recognized by cell surface sialic acid-binding immunoglobulin-like lectin (Siglec) proteins, which are the inhibitory receptors of the Ig superfamily and have two cytoplasmic immunoreceptor tyrosine-based inhibition motifs, the authors examined the role of Siglec-10 in the suppressive effect of CD52 hi CD4 1 T cells. Blocking Siglec-10 with an antibody against the extracellular domain of Siglec-10 or through a soluble Siglec-10-Fc fusion protein, reversed the inhibitory effect of CD52 hi CD4 1 T cells. Thus, a novel ligand for the suppressive action of CD52 on this novel regulatory subset was identified (Figure 1) .
CD52 is only 12-amino acid long, and it is a heavily glycosylated glycopeptide that is tethered into the cell membrane through a glycosylphosphatidylinositol anchor (Figure 1) . 7 This peptide is abundantly expressed on all human lymphocytes and male reproductive tissues, including mature sperm cells. Alemtuzumab, a humanized monoclonal antibody against CD52, has been widely used for the depletion of T cells to prevent graftversus-host diseases in bone marrow transplantation and in the treatment of lymphoma. 8 Interestingly, CD52 was also shown to be costimulatory for the induction of adaptive Tregs. 9 Phospholipase is required for the cleavage and release of soluble CD52, but its preference for cleaving elevated versus normally expressed CD52 on T cells remains to be addressed. It is also unknown how Tregs replenish CD52 after cleavage to maintain their inhibitory functions. One might hypothesize that the cleavage and release of CD52 from normal cells may provide an inhibitory function in this setting. It is possible that the loss of CD52 may render regulatory T cells into conventional T cells at least transiently, and this transition may regulate the feedback mechanism for the regulatory cells. Inhibitors of phospholipase C may have a therapeutic effect by targeting immunosuppressive T cells. This action may release the suppression of effector memory cells, resulting in a defense against cancer cells or pathogenic microorganisms. Another interesting question that remains to be addressed is why there were no CD25
1

CD4
1 Tregs identified in the suppressive T-cell clones, despite previous studies demonstrating that CD4
1
CD25
1 Tregs play a critical role in the prevention of type 1 diabetes. 10, 11 A possible explanation is that the GAD65 antigen may preferentially activate nonconventional Tregs. It was previously reported that GAD65-specific TCR transgenic T cells prevented the development of diabetes in NOD mice in a CD4
1
CD25
1 T cell-independent manner.
12 Thus, this group identified a novel T-cell population with regulatory functions, and this study may lead to novel therapeutic options for autoimmune diseases, cancer and infectious diseases. 
